CION Ameerpet
Someone has mentioned HIPEC, and it has arrived sounding like the thing that changes everything. It helps a specific group of women, in one specific situation, and it is not part of most ovarian cancer operations. Here is what it actually is, where the evidence is genuinely strong, and what to ask before you agree to it.
HIPEC stands for hyperthermic intraperitoneal chemotherapy: chemotherapy, heated, and washed directly through the abdominal cavity. It is given once, in the operating theatre, immediately after a surgeon has removed as much of the cancer as possible. Catheters are placed into the abdomen, a warmed chemotherapy solution is circulated through it by a pump for roughly sixty to ninety minutes, and then it is drained out and the abdomen is closed.
If you have been searching HIPEC ovarian cancer since a doctor mentioned it in passing, the most useful thing to understand first is what it is not. It is not a course of treatment. It is not an alternative to the chemotherapy given through a drip — women who have HIPEC still have their full course of that. And it is not an operation in its own right: it is an addition to debulking (cytoreductive) surgery, performed under the same anaesthetic, that only makes sense once that surgery has gone well.
The logic behind it is specific to how ovarian cancer behaves. Rather than travelling mainly through the bloodstream, it sheds cells that settle across the lining of the abdomen — the peritoneum — like seeds scattered on a surface. Chemotherapy given into a vein reaches that lining relatively poorly. Chemotherapy poured directly into the abdomen reaches it at a far higher concentration, and warming the solution to around 41–43°C makes the drug more toxic to cancer cells and helps it soak a few millimetres deeper into tissue. A few millimetres is the entire point of HIPEC, and also its entire limitation.
The solution is held at roughly 41–43°C and monitored continuously. Heat is directly toxic to cancer cells and increases how deeply a platinum-based agent penetrates tissue. It is not a mild warming — it is a controlled, measured temperature held for the length of the perfusion.
Delivered into the abdominal cavity rather than a vein, the chemotherapy bathes the peritoneal surfaces at a concentration a drip could never safely achieve, while comparatively little of it crosses into the bloodstream to cause whole-body effects.
HIPEC is a single perfusion of about 60–90 minutes under the same anaesthetic as the surgery. That is what separates it from IP chemotherapy, which is unheated and repeated over weeks through an implanted port.
HIPEC has been performed for decades in other abdominal cancers, but it only entered mainstream ovarian cancer guidelines recently, and on the strength of a single randomised trial. In 2018 the OVHIPEC-1 trial, published in the New England Journal of Medicine, tested adding one dose of heated intraperitoneal chemotherapy to interval cytoreductive surgery in women with stage III ovarian cancer whose disease had responded to chemotherapy given first. Adding HIPEC lengthened both recurrence-free and overall survival, without a meaningful rise in the rate of serious complications. Guidelines now list HIPEC as an option that may be considered at interval cytoreduction — an option, in one defined situation, and not a routine part of every ovarian cancer operation. Source: van Driel WJ et al., New England Journal of Medicine (2018); NCCN Ovarian Cancer guidelines.
Three different ways of getting chemotherapy to ovarian cancer. They are routinely confused, including in clinic, and the differences change what you are actually being asked to consent to.
| Approach | How and when it is given | What it reaches best | The honest trade-off |
|---|---|---|---|
| Intravenous (drip) chemotherapy | Through a vein in a day-care chair, usually as a course of cycles some weeks apart, before and after surgery. Delivered in-house at CION across 35+ centres. | The whole body — including disease outside the abdomen and microscopic cells in lymph nodes. This is the backbone of treatment. | Reaches the peritoneal surfaces at a lower concentration than direct delivery, and produces whole-body side effects. |
| HIPEC | A single heated perfusion of the abdomen lasting 60–90 minutes, in theatre, at the end of cytoreductive surgery. Delivered at specialist partner centres. | Microscopic disease sitting on the peritoneal lining, to a depth of only a few millimetres. | Adds time, risk and cost to an already major operation, and the randomised evidence supports it in one situation rather than all. |
| IP (intraperitoneal) chemotherapy | Through a catheter and implanted port into the abdomen, repeated over several cycles in the weeks after surgery. Not heated. | The same peritoneal surfaces, but repeatedly over weeks rather than once in theatre. | Poorly tolerated by many women, with catheter problems common. Its use has declined as later trials failed to confirm the early benefit. |
*None of these substitutes for removing the cancer. Every intraperitoneal approach depends on there being almost nothing left behind for the chemotherapy to have to reach. For the wider picture of how these fit together, see the complete ovarian cancer guide.
HIPEC has one setting where a randomised trial supports it, and several where it is still being studied. Knowing which of these you are in is the difference between an informed decision and a hopeful one.
This is the situation OVHIPEC-1 studied, and the only one guidelines currently endorse. It applies to women whose cancer was too extensive to remove safely at the outset, who were given chemotherapy first to shrink it, and who then went to interval cytoreductive surgery once it had responded. HIPEC was added at that operation, as a single perfusion.
If that describes your pathway, HIPEC is a reasonable thing to discuss and to ask about specifically, because it will not be offered everywhere. If your pathway is different, the honest position is that you are outside the evidence — which is not the same as it being useless, but it is not the same as it being proven either.
Heated chemotherapy penetrates roughly two to three millimetres of tissue. That is not a technicality — it decides who HIPEC can help. If nodules larger than that are still present when the perfusion runs, the solution washes over their surface and never reaches the middle of them.
So HIPEC does not rescue an incomplete operation, and no amount of heat compensates for disease left behind. It is an adjunct to a successful cytoreduction, not a substitute for one. This is also why the surgeon's judgement on the day carries more weight than the plan made in clinic.
HIPEC added at the first operation, before any chemotherapy has been given, is a different clinical scenario from the one that was tested, and the results in that setting have not been consistent. It is not currently a guideline-endorsed option for routine use at upfront surgery.
If it is proposed at a primary operation, the reasonable questions are what evidence it is being based on, whether a clinical trial is available, and what it adds to the operating time and the recovery. A clear answer to those is a sign of a good unit.
Trials of HIPEC alongside surgery for recurrent ovarian cancer have produced conflicting results, with some showing a benefit and others none. Selection explains a good deal of the disagreement: women chosen for repeat surgery are usually those doing well anyway, which makes any single-arm result difficult to interpret.
Related intraperitoneal techniques such as PIPAC — pressurised aerosolised chemotherapy delivered by laparoscopy — are being studied mainly for symptom control in advanced peritoneal disease rather than as a route to cure. Both belong in a trial or a carefully counselled discussion, not on a standard menu. Options at this stage are covered on the ovarian cancer treatment page.
Cytoreductive surgery with HIPEC is long, and it is followed by intensive-care monitoring. Kidney function, heart and lung reserve, nutritional state and how well you recovered from chemotherapy all weigh on the decision, sometimes more heavily than the stage on the scan.
Age alone does not disqualify anyone, but frailty is a genuine contraindication. A team that declines HIPEC on fitness grounds and proceeds with the cytoreduction alone is making a defensible decision, not a lesser one.
The evidence comes from epithelial ovarian cancer, and predominantly from high-grade serous disease, which is the type that spreads across the peritoneum in the pattern HIPEC is designed to address.
Germ cell tumours and sex cord-stromal tumours behave quite differently, are usually far more chemosensitive or far more indolent, and are managed on different pathways. HIPEC has no established role in them, and being offered it for a rare subtype warrants a second opinion.
HIPEC is a real treatment with real randomised evidence behind it in one defined setting. It is also, for exactly that reason, sometimes offered where it does not belong. These are the signs worth pausing on.
There is no standalone version. Heated chemotherapy is given in theatre, at the end of a cytoreductive operation. An offer that does not include the surgery is not HIPEC.
HIPEC is abandoned in theatre when too much disease remains, because the solution cannot penetrate more than a few millimetres. A team that has not raised this possibility before consent has not prepared you for the commonest reason it will not go ahead.
HIPEC does not replace intravenous chemotherapy and does not remove the need for maintenance therapy where testing supports it. Anyone presenting it as an alternative to either has misunderstood what it does.
The evidence sits in epithelial, largely high-grade serous disease. Germ cell and stromal tumours follow different pathways, and HIPEC has no established role in them.
HIPEC adds theatre time, disposable perfusion equipment and intensive care to the bill, and insurance or scheme cover for it varies. A unit unwilling to put the figure in writing before consent is worth questioning — see HIPEC cost for ovarian cancer.
Cytoreduction with HIPEC is a high-volume, team-dependent operation. It is entirely fair to ask how many the centre performs each year and who will be in theatre.
None of these means HIPEC is wrong for you. Each is a reason to get a second opinion while the plan can still change, rather than after the operation is booked. A specialist review of your imaging, pathology and chemotherapy response takes one consultation — and it is free at CION.
HIPEC is decided alongside the chemotherapy and surgical plan, not afterwards. A 45-minute consultation gets your scans, pathology and treatment history in front of a tumour board while the decision is still open.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If HIPEC is not right for your situation, we will say so plainly and explain what is.
One number is worth holding on to before anything else: HIPEC adds roughly ninety minutes to an operation that is already among the longest in gynaecological surgery. This is what fills those hours, and the days after them.
HIPEC cannot be arranged on the morning of surgery — the perfusion apparatus and a trained theatre team have to be booked. The decision is made at a tumour board that reviews your CT scan, your pathology, how well the cancer responded to chemotherapy, your kidney function and your general fitness. If HIPEC is being considered, ask at this stage, not later.
The operation begins as a standard cytoreductive procedure: removal of the ovaries, fallopian tubes, uterus and omentum, stripping of involved peritoneum, and sometimes resection of a segment of bowel or disease from the surface of the diaphragm. The aim is no visible cancer remaining. This is the part that does most of the work.
HIPEC only proceeds if what remains is small enough for it to reach. If the surgical team cannot get to that point, the perfusion is abandoned and the operation is closed without it — and that is the correct call, not a failure. Your consent form should say so explicitly, so that nobody is surprised afterwards.
Catheters and temperature probes are placed in the abdomen and connected to a circuit. A platinum-based agent in a warmed carrier solution is circulated at around 41–43°C for 60–90 minutes while your temperature, blood pressure and urine output are watched closely. The abdomen is gently agitated so the solution reaches every surface. The fluid is then drained and the abdomen closed.
Expect at least one night in intensive care or a high-dependency unit. Kidney function and blood counts are checked repeatedly, fluids are given generously to protect the kidneys, and drains and a urinary catheter stay in for some days. Bowel function is often slow to restart, so eating returns gradually. The hospital stay is meaningfully longer than for debulking surgery alone.
Once the wound has healed and counts and kidney function have recovered, the remaining cycles of intravenous chemotherapy resume, followed by maintenance therapy where BRCA or HRD testing supports it. This part of your care is delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh, so it can happen near where you live.
The operation and the perfusion both happen at a specialist partner centre, with gynaecologic-oncology surgeons and the equipment HIPEC requires, and may be billed there. CION plans the pathway, delivers the chemotherapy and maintenance treatment around it, and stays with you through follow-up. See the HIPEC service page for the coordination details.
Most of the risk in a HIPEC operation belongs to the cytoreduction rather than to the perfusion: bleeding, infection, blood clots, and problems with any bowel join made during the surgery. Those risks exist whether or not HIPEC is added, and they are the reason this operation is done in high-volume units by teams who do it often.
HIPEC adds its own burden on top. The kidneys carry the main load, because a platinum-based agent absorbed from the abdominal cavity is cleared through them; blood counts drop; the bowel commonly takes longer to wake up; and the hospital stay lengthens. In the randomised trial that supports its use, adding HIPEC did not meaningfully increase the rate of serious complications — but every woman in that trial had already been judged fit for major surgery. That is a finding about a selected group, not a reassurance that HIPEC is a small addition.
Cost is the question people find hardest to ask, and it deserves a straight answer rather than a brochure. HIPEC lengthens theatre time, requires disposable perfusion equipment, and usually means intensive care, so it costs more than the same operation without it, and insurance and scheme cover for it varies. Ask for a written, itemised estimate before you consent, and ask specifically whether the perfusion is covered separately from the surgery. We have set out what drives the figure on HIPEC cost for ovarian cancer.
The main organ-specific concern. Function is checked before the operation, protected with fluids during and after the perfusion, and monitored for days afterwards. Pre-existing kidney impairment can be the reason a team declines HIPEC.
The recovery is the cytoreduction's recovery, extended. Slower return of bowel function, a longer stay, and often several weeks before you feel functional at home. Ask for a realistic timeline for your own situation rather than an average.
If the surgical team cannot remove enough disease, HIPEC does not go ahead. Knowing that in advance turns a distressing surprise into an expected possibility, and it is a sign of a team applying the evidence properly.
Theatre time, disposables and intensive care all add up, and cover varies between insurers and schemes. An itemised written estimate before consent is a reasonable thing to insist on, and any good unit will provide one.
HIPEC is a decision that gets made badly when it is made quickly. It depends on the stage, on how the cancer responded to chemotherapy, on whether a complete cytoreduction is realistic, and on whether you are fit for the recovery — and those four things sit with four different specialists. That is the argument for a tumour board rather than a single opinion, and for a consultation long enough to actually look at your scans and reports.
Your first consultation at CION is free and runs to about 45 minutes. Every case is discussed at a tumour board — medical oncology, surgical oncology, radiology and pathology together — before a plan is offered. If HIPEC is appropriate for your situation we will say so and arrange it; if you are outside the evidence for it, we will say that too, and explain what actually changes your outcome instead.
We are also plain about who does what. Cytoreductive surgery and HIPEC itself are coordinated with specialist gynaecologic-oncology surgeons at partner centres, and may be billed there. What CION delivers in-house is the medical oncology: chemotherapy before and after surgery, maintenance therapy, BRCA and HRD testing, genetic counselling, nutrition support, survivorship care and follow-up, across 35+ centres in Telangana and Andhra Pradesh. You are told which is which before anything is booked, not after.
For context on outcomes across our ovarian cancer patients as a whole: 81.0% of CION patients are alive at one year, against a national figure of 73.7%. These are one-year figures for a treated population, not cure rates and not a prediction for any individual — your own outlook depends on stage, subtype, how completely the surgery goes and your general health, and is a conversation to have with your oncologist.
Free, unhurried, and long enough to read your scans and reports properly rather than glance at a summary. Bring the CT images, the histopathology report and the chemotherapy record if you have them.
Whether HIPEC belongs in your plan is settled by a multidisciplinary group looking at imaging, pathology and response together. Care led by a team, not a single doctor's preference.
The systemic treatment around the operation — before, after and as maintenance where testing supports it — is delivered by CION across 35+ centres, so it can happen close to home.
Both are coordinated with specialist partner centres and may be billed there. We would rather tell you that in the first consultation than have you discover it on an invoice.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
HIPEC stands for hyperthermic intraperitoneal chemotherapy. At the end of an operation to remove ovarian cancer, while you are still under anaesthetic, a chemotherapy solution is warmed to around 41 to 43 degrees Celsius and circulated through the abdominal cavity for about sixty to ninety minutes, then drained out. It is given once, not as a course. The reasoning is that ovarian cancer spreads by settling on the lining of the abdomen, and chemotherapy delivered directly onto that lining reaches it at a far higher concentration than a drip can, with the heat helping it penetrate a few millimetres deeper. It is an addition to cytoreductive surgery, never a replacement for it.
It is not a competitor to it. Intravenous chemotherapy remains the backbone of ovarian cancer treatment because it reaches the whole body, including any disease outside the abdomen and microscopic cells in lymph nodes. HIPEC treats one thing well: microscopic disease sitting on the peritoneal surfaces, to a depth of a few millimetres. Women who have HIPEC still receive their full course of intravenous chemotherapy before and after surgery, and often maintenance therapy afterwards. In one randomised trial, in stage III disease at interval surgery, adding HIPEC to that standard pathway improved outcomes. Adding, not replacing, is the operative word — and outside that setting the evidence is not settled.
A narrower group than most people expect. The evidence guidelines rely on comes from women with stage III epithelial ovarian cancer whose disease was too extensive to remove at the outset, who had chemotherapy first, and who then had interval cytoreductive surgery, with HIPEC added at that operation. Two further conditions matter as much as the stage. The surgeon must have removed essentially all visible disease, because heated chemotherapy penetrates only two to three millimetres and cannot reach the centre of anything larger. And you must be fit enough for a long operation and an intensive-care recovery. At upfront surgery and at recurrence the evidence is unsettled, and HIPEC there is best done within a clinical trial.
The perfusion itself runs about sixty to ninety minutes, but it sits inside a cytoreductive operation that commonly lasts several hours on its own. Expect a night or more in intensive care or a high-dependency unit, drains and a catheter for some days, and a hospital stay meaningfully longer than for debulking surgery without HIPEC. Bowel function is often slow to restart, so eating returns gradually. Most women are looking at several weeks before they feel functional at home, and longer before they feel like themselves. Systemic chemotherapy usually resumes once the wound has healed and blood counts and kidney function have recovered. Ask your team for a timeline based on your own situation before you consent.
Most of the risk belongs to the cytoreductive surgery rather than the perfusion: bleeding, infection, blood clots, and problems with any bowel join made during the operation. HIPEC adds its own burden on top — stress on the kidneys, a fall in blood counts, a longer period before the bowel starts working, and a longer hospital stay. In the randomised trial supporting its use, adding HIPEC did not substantially increase the rate of serious complications, but that was in women already selected as fit for major surgery, so it should not be read as a minor addition. Kidney function is monitored closely during and after the perfusion, and fluids are given generously to protect it.
HIPEC is available in Hyderabad at specialist centres equipped with the perfusion apparatus and staffed by gynaecologic-oncology surgical teams. It cannot be done on its own. HIPEC is always given under the same anaesthetic as cytoreductive surgery, once the surgeon has removed as much disease as possible — there is no version delivered as an outpatient treatment or a series of infusions. If someone offers you heated chemotherapy without surgery, that is not HIPEC. At CION the operation and the perfusion are coordinated with specialist partner centres and may be billed there, while your chemotherapy, maintenance therapy and follow-up are delivered in-house.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house — chemotherapy before and after surgery, maintenance therapy, BRCA and HRD testing, genetic counselling, nutrition support and follow-up, across more than 35 centres in Telangana and Andhra Pradesh. Cytoreductive surgery and HIPEC itself are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered on an invoice. Whether HIPEC is appropriate is decided at a tumour board that reviews your imaging, pathology and response to chemotherapy, not by one doctor in one clinic.